Xenon Pharmaceuticals

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Xenon Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 5 currently recruiting 5 completed later-stage tilt top decile by trial count

Xenon Pharmaceuticals: 13 sponsored US clinical trials, 5 recruiting.

Xenon Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 5 completed. 8 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Focal Onset Seizures, with 2 trials.

Top-decile sponsor footprint

Xenon Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07172516
RECRUITING Phase 3

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

NCT07076407
RECRUITING Phase 3

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

NCT06775379
RECRUITING Phase 3

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100
RECRUITING Phase 3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142
ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962
COMPLETED Phase 3

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

NCT05614063
COMPLETED Phase 2

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

NCT05376150
TERMINATED Phase 3

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
TERMINATED Phase 3

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310
COMPLETED Phase 1

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

NCT01486446
COMPLETED Phase 2

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

NCT01195636
COMPLETED Phase 2

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

NCT00954356

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 8

Therapeutic Areas

Focal Onset Seizures 2
Major Depressive Disorder 2
Dental Pain 1
Primary Generalized Tonic-Clonic Seizures 1
Bipolar II Disorder 1
Bipolar I Disorder 1
Focal Epilepsy 1
Bipolar Disorder 1
Bipolar Depression 1

Where Xenon Pharmaceuticals enrollment is open (later-stage tilt)

5 recruiting of 13 indexed (38% open); 5 completed (38%).

Phase mix: 8 late (III/IV) vs 5 early (I/II) (later-stage heavy).

Top condition: Focal Onset Seizures (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Xenon Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 13 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Xenon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1020304050 0%10%20%30%40%50% Total trials Recruiting share Xenon PharmaceuticalsAdaptimmuneAgennixAkili Interactive LabsAlumisMorehouse School of MedicineNortheastern UniversityThomas HopeWilliam Stoops
Xenon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Xenon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Xenon Pharmaceuticals page

13 registered trials is a research-attention snapshot, not an endorsement of Xenon Pharmaceuticals or any single study.

  • 5 of Xenon Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Focal Onset Seizures is the condition Xenon Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Focal Onset Seizures trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Xenon Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.